ReviewSubstance abuse and rehabilitation2016
Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review.
Review in Substance abuse and rehabilitation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 55 citations in OpenAlex.
- Exogenous progesterone for cannabis withdrawal in women: Feasibility trial of a novel multimodal methodology.Pharmacology, biochemistry, and behavior · 2019Trial
- Predictors of Topiramate Tolerability in Heavy Cannabis-Using Adolescents and Young Adults: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial.Journal of clinical psychopharmacology · 2018Trial
- Trial
- A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.Drug and alcohol dependence · 2017Trial
- Development of Mobile Contingency Management for Cannabis Use Reduction.Behavior therapy · 2024Article
- Interventions for cannabis use disorder.Current opinion in psychology · 2021Review
- Reciprocal Influences of HIV and Cannabinoids on the Brain and Cognitive Function.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020Review
- Higher average potency across the United States is associated with progression to first cannabis use disorder symptom.Drug and alcohol dependence · 2019Article
- An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use.European archives of psychiatry and clinical neuroscience · 2019Review
- Clinical Practice Guidelines on Assessment and Management of Substance Abuse Disorder in Children and Adolescents.Indian journal of psychiatry · 2019Article
- Emergency Department Burden of Nausea and Vomiting Associated With Cannabis Use Disorder: US Trends From 2006 to 2013.Journal of clinical gastroenterology · 2018Article
- Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal.British journal of pharmacology · 2018Article
- Chronic ΔThe Journal of pharmacology and experimental therapeutics · 2018Article
- Prevalence and correlates of treatment utilization among adults with cannabis use disorder in the United States.Drug and alcohol dependence · 2017Article
- Cannabis Withdrawal: A Review of Neurobiological Mechanisms and Sex Differences.Current addiction reports · 2017Article
- The cannabis withdrawal syndrome: current insights.Substance abuse and rehabilitation · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabis is the most widely used and variably regulated drug in the world, with increasing trends of use being reported in the US, Australia, Asia, and Africa. Evidence has shown a decrease in the age of commencement of cannabis use in some developed countries and a prolongation of risk of initiation to cannabis use beyond adolescence among more recent users. Cannabis use is associated with numerous health risks and long-term morbidity, as well as risk of developing cannabis-use disorders. Cannabis users infrequently seek professional treatment, and normally do so after a decade of use. Cannabis-use disorders are currently treated using a selection of psychosocial interventions. Severity of withdrawal is a factor that increases the risk of relapse, and is the target of pharmacotherapy studies. Currently, there is no approved pharmacotherapy for cannabis-use disorders. A number of approaches have been examined, and trials are continuing to find a safe and effective medication with little abuse liability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.